Management of BRAF-mutant metastatic colorectal cancer

被引：2
|
作者：
Burge, Matthew [1 ,2 ]
Whitehall, Vicki [2 ,3 ,4 ]
机构：
[1] Royal Brisbane & Womens Hosp, Brisbane, Qld, Australia
[2] Univ Queensland, Brisbane, Qld, Australia
[3] QIMR Berghofer Med Res Inst, Brisbane, Qld, Australia
[4] Pathol Queensland, Brisbane, Qld, Australia
来源：
COLORECTAL CANCER | 2016年 / 5卷 / 04期
关键词：
BRAF; colorectal cancer; metastasis; therapy;
D O I：
10.2217/crc-2016-0012
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：131 / 133
页数：3
相关论文
共 50 条
  • [31] Probing synthetic lethal interactions with RAF inhibition in BRAF-mutant colorectal cancer
    Whittaker, Steven R.
    Luo, Flora
    Hsiao, Jessica
    Cowley, Glenn S.
    Root, David E.
    Garraway, Levi A.
    MOLECULAR CANCER THERAPEUTICS, 2013, 12 (05)
  • [32] Comment on: "Exploring the best treatment options for BRAF-mutant metastatic colon cancer"
    Milano, Gerard
    Gal, Jocelyn
    BRITISH JOURNAL OF CANCER, 2020, 122 (11) : 1724 - 1725
  • [33] Management of a Patient With Advanced BRAF-Mutant Melanoma
    Ashworth, Michelle T.
    Daud, Adil
    JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2014, 12 (03): : 315 - 319
  • [34] Curcumin chemoprevention reduces the incidence of BRAF-mutant colorectal cancer in a preclinical study
    Kane, A.
    Liu, C.
    Akhter, D.
    Mckeone, D.
    Bell, C.
    Thurecht, K.
    Leggett, B.
    Whitehall, V.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2020, 35 : 162 - 163
  • [35] ATYPICAL PRESENTATIONS OF BRAF-MUTANT COLORECTAL CANCER: CASE REPORT AND LITERATURE REVIEW
    Nishimura, Yoshito
    JOURNAL OF GENERAL INTERNAL MEDICINE, 2017, 32 : S453 - S453
  • [36] A Phase Ib Dose-Escalation Study of Encorafenib and Cetuximab with or without Alpelisib in Metastatic BRAF-Mutant Colorectal Cancer
    van Geel, Robin M. J. M.
    Tabernero, Josep
    Elez, Elena
    Bendell, Johanna C.
    Spreafico, Anna
    Schuler, Martin
    Yoshino, Takayuki
    Delord, Jean-Pierre
    Yamada, Yasuhide
    Lolkema, Martijn P.
    Faris, Jason E.
    Eskens, Ferry A. L. M.
    Sharma, Sunil
    Yaeger, Rona
    Lenz, Heinz-Josef
    Wainberg, Zev A.
    Avsar, Emin
    Chatterjee, Arkendu
    Jaeger, Savina
    Tan, Eugene
    Maharry, Kati
    Demuth, Tim
    Schellens, Jan H. M.
    CANCER DISCOVERY, 2017, 7 (06) : 610 - 619
  • [37] Randomized trial of irinotecan and cetuximab with or without vemurafenib in BRAF-mutant metastatic colorectal cancer (SWOG S1406).
    Kopetz, Scott
    McDonough, Shannon L.
    Lenz, Heinz -Josef
    Magliocco, Anthony Martin
    Atreya, Chloe Evelyn
    Diaz, Luis A.
    Allegra, Carmen Joseph
    Raghav, Kanwal Pratap Singh
    Morris, Van Karlyle
    Wang, Stephen E.
    Lieu, Christopher Hanyoung
    Guthrie, Katherine A.
    Hochster, Howard S.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [38] Randomized Trial of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF-Mutant Metastatic Colorectal Cancer (SWOG S1406)
    Kopetz, Scott
    Guthrie, Katherine A.
    Morris, Van K.
    Lenz, Heinz-Josef
    Magliocco, Anthony M.
    Maru, Dipen
    Yan, Yibing
    Lanman, Richard
    Manyam, Ganiraju
    Hong, David S.
    Sorokin, Alexey
    Atreya, Chloe E.
    Diaz, Luis A.
    Allegra, Carmen
    Raghav, Kanwal P.
    Wang, Stephen E.
    Lieu, Christopher H.
    McDonough, Shannon L.
    Philip, Philip A.
    Hochster, Howard S.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (04) : 285 - +
  • [39] RAS and BRAF in metastatic colorectal cancer management
    Gong, Jun
    Cho, May
    Fakih, Marwan
    JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2016, 7 (05) : 687 - 704
  • [40] Dabrafenib and Trametinib, Alone and in Combination for BRAF-Mutant Metastatic Melanoma
    Menzies, Alexander M.
    Long, Georgina V.
    CLINICAL CANCER RESEARCH, 2014, 20 (08) : 2035 - 2043
12345